Navigation Links
IVI announces the prequalification of innovative cholera vaccine by the World Health Organization
Date:11/11/2011

SEOUL, KOREA -- Shanchol, a new oral cholera vaccine developed through the International Vaccine Institute (IVI), an international organization established by the United Nations and based in Seoul, recently received prequalification from the World Health Organization (WHO). Developed for use in developing countries to protect against life-threatening cholera, Shanchol is ready to use in a single-dose vial and is administered orally, which facilitates its implementation in large-scale immunization programs. Shanchol is produced by Shantha Biotechnics part of the Sanofi group - in India where the vaccine has been licensed and sold since 2009.

"I am immensely pleased by the news that Shanchol, a vaccine enabled by IVI, received WHO prequalification," said Dr. Christian Loucq, IVI's new Director General. "This stamp of approval shows that public-private partnerships - such as those among IVI, Vabiotech, Shantha and Sanofi are essential for successful vaccine development, particularly in developing vaccines against neglected diseases of the poor like cholera."

Certification by WHO of Shanchol represents a major milestone as it indicates that the vaccine meets WHO standards of quality, safety and efficacy, and allows the vaccine to be procured by UN agencies and other international organizations for use in countries around the world. It also accelerates international use of the vaccine since WHO prequalification eliminates the need for country-level market authorization in some countries, which can take years to obtain.

WHO prequalification of Shanchol is the latest achievement in IVI's mission to develop and introduce innovative, safe, and effective vaccines to protect vulnerable populations in poor countries against deadly diseases including cholera. With financial support from the Bill & Melinda Gates Foundation and the governments of Korea and Sweden, and technical support from scientists in Sweden, as well as at Vietnam's National Institute of Hygiene and Epidemiology and production experts at Shantha, IVI enabled technology transfer from Vabiotech, a vaccine manufacturer in Vietnam, to Shantha for the production of cholera vaccine. IVI also established and transferred tests to ensure the vaccine was of the highest quality and enabled improvements in production to keep manufacturing costs as low as possible.

"This important milestone validates Vabiotech's efforts and technical capability in developing and promoting the manufacture of an affordable cholera vaccine for the world's poorest people," said Dr. Nguyen Thu Van, Director General of Vabiotech. "We are eager to see this vaccine rapidly deployed, especially in endemic areas, amid recent outbreaks of cholera in Africa, Asia and the Caribbean."

A Phase III clinical trial performed by IVI and colleagues at India's National Institute of Cholera and Enteric Diseases was launched at a field site in Kolkata to evaluate the vaccine in people from ages one year and up. The results showed the vaccine to be safe and protective against cholera for three years in all age groups. Licensed in India in 2009, Shanchol was the first vaccine to be developed and licensed from the pipeline of vaccines being developed with support from the Bill & Melinda Gates Foundation

"Prequalification of the Shanchol vaccine by WHO represents a validation of Shantha's quality processes and the safety and efficacy of the vaccine," said Dr. Harish Iyer, Chief Executive Officer of Shantha Biotechnics. "This approval also reinforces our commitment to work with partners to provide vaccines against infectious diseases affecting developing countries."

The prequalification by WHO sets the stage for IVI's next planned phase of the vaccine, which is introducing Shanchol in countries where cholera remains a major public health problem, such as countries in Africa and South Asia where the disease is endemic. Recently IVI estimated that nearly 3 million cases requiring treatment and about 94,000 deaths are due to cholera in endemic countries. The large outbreak that erupted in Haiti in October 2010 demonstrates that the incidence and severity of the disease can shift dramatically over a short period of time. The Haitian health ministry reported that this outbreak had caused 194,095 cumulative cases and 3,819 deaths by January 16, 2011.

Also, West and Central Africa have recently been besieged by a major outbreak across the region. According to UNICEF, 85,000 cholera cases and 2,466 deaths have been reported this year so far, potentially making it one of the worst outbreaks in the region's history. Deploying Shanchol, in conjunction with other preventive interventions and treatment, could play a key role in saving lives both in countries where the disease is endemic and in settings of natural disasters or humanitarian crises.

"In light of the devastating cholera outbreaks in Haiti, Pakistan, Nepal and in several countries of Africa, there is a clear need for a solution to halt the countless deaths and suffering," said Dr. Loucq. "A vaccine like Shanchol should positively impact public health efforts to control cholera in these countries. Now that Shanchol is WHO prequalified, IVI is looking forward to working with governments and other organizations to introduce this vaccine and to make it widely available for use around the world."

"This demonstrates the power of vaccines to prevent epidemic diseases in people at risk," said Dr. Regina Rabinovich, Director of Infectious Diseases at the Bill & Melinda Gates Foundation. "We must continue to work together to ensure that everyone has access to affordable vaccines, no matter where they live."


'/>"/>
Contact: Tae Kyung Byun
tkbyun@ivi.int
82-119-773-6071
International Vaccine Institute
Source:Eurekalert

Related medicine news :

1. AMRI announces collaboration agreement with Lilly for in-sourced chemistry services
2. University of Michigan announces Eric J. Topol Professorship in Cardiovascular Medicine
3. Peter Thiel announces Breakout Labs to energize innovation
4. ESC announces review of Atrial Fibrillation Guidelines
5. The Waxman Foundation announces $25,000 grant in B-cell lymphoma research
6. INFORMS journal announces special issue on using logistics, analytics in humanitarian relief
7. ASTRO announces 2011 Fellows class
8. The New York Stem Cell Foundation announces new initiative for Parkinsons disease
9. AFAR announces the 2011 Hartford Scholars in Geriatric Medicine
10. AGA announces prestigious recognition award recipients
11. Sanofi Pasteur announces FDA approval of menactra meningococcal conjugate vaccine indication for infants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder of ... ElderCounsel, a national organization of elder law and special needs planning attorneys. “Membership in ... It also provides a forum to network with elder law attorneys nationwide,” said Somekh. ...
(Date:10/13/2017)... OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... or dementia. However, many long-term care insurance companies have a waiver for care if ... the 90-day elimination period, when the family pays for care, is often waived, so ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Ellevate Network, ... in business to advocate for action towards gender equality at their inaugural Summit in ... around the globe, and reached a social audience of over 3 million. To watch ...
(Date:10/13/2017)... Abilene, Texas (PRWEB) , ... October 13, 2017 , ... ... publication this week that explains one of the most popular and least understood books ... seems like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in agile ... a contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise ... use of Agile methodologies in a consistent and high value manner across CMS ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... MIAMI , Sept. 27, 2017  Commended for their ... recent notable awards. Ranked as number one in the South ... ninth time in Inc. 5000 yearly list, the national specialty ... CEO, Armando Bardisa will soon be honored by ... Set to receive his award ...
(Date:9/22/2017)... , Sept. 22, 2017  As the latest Obamacare ... Bill Cassidy (R-LA) and Lindsey Graham ... that the medical device industry is in an odd ... tax, the 2.3% excise tax on medical device sales ... also want covered patients, increased visits and hospital customers ...
(Date:9/18/2017)... PROVIDENCE, R.I. , Sept. 18, 2017 ... in the fields of bioinformatics and immune ... to develop a protective avian influenza A (H7N9) vaccine. ... is distantly related to seasonal influenza and ... approaches, which rely on prior exposure to be ...
Breaking Medicine Technology: